abliva - abliva’s upcoming phase 2/3 study with kl1333 - world mitochondrial disease week 2022
Published 2 years ago • 201 plays • Length 3:43Download video MP4
Download video MP3
Similar videos
-
2:30
abliva - kl1333 and the upcoming phase 2/3-study
-
3:52
abliva - drug development in mito disease - world mitochondrial disease week 2022
-
2:32
abliva - introducing mitochondrial “mito” disease - world mitochondrial disease week 2022
-
4:55
abliva - living with mitochondrial disease - world mitochondrial disease week 2022
-
3:47
abliva - a patient-centric approach to drug development - world mitochondrial disease week 2022
-
9:35
abliva - living with mitochondrial disease: full interview - world mitochondrial disease week 2022
-
2:36
abliva - introducing mitochondrial “mito” disease
-
1:06:30
abliva - kol event on kl1333 in primary mitochondrial disease, may 21, 2024
-
3:46
abliva - primary mitochondrial disease and nad /nadh
-
3:41
abliva - drug development - mito disease
-
2:42
abliva - developing the promis fatigue mitochondrial disease short form
-
0:28
abliva - world mitochondrial disease week 2023
-
2:16
abliva - about lead candidate kl1333
-
15:52
abliva’s innovative drug development programs for primary mitochondrial diseases, m. hansson
-
2:51
abliva - living with mito disease
-
1:36
abliva – what is mitochondrial disease?
-
18:36
biostock investor meeting | abliva | march 2023